Award
NIH Reporter #75N93023C00042-0-9999-1
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
Recipient
INIMMUNE CORPORATION, MISSOULA, MT, UNITED STATES
Award Amount
$1,744,408.00
Ceiling
$1,744,408.00
Awarded
September 30, 2023
Identifier
75N93023C00042-0-9999-1
Award for developing a synthetic adjuvant system for influenza vaccines, funded by NIAID, with a focus on optimization, scale-up, and production for IND submission.
Description
The project involves developing a synthetic adjuvant system for influenza vaccines, partnering a synthetic TLR4 agonist with a semi-synthetic saponin. The project aims to optimize, scale-up, and produce cGMP SAS for IND submission. The project is funded by NIAID and is part of a multi-year effort.